Emergent BioSolutions, Inc. (EBS)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$6.21-0.32%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · EBS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | 742.9 | 1,043.6 | 1,049.3 | 1,117.5 | 1,773.6 | 1,577.3 | 1,106.0 | 782.4 | 560.9 | 488.8 | 522.8 | 450.1 | 312.7 | 281.9 | 273.4 |
| Total Revenues | — | 742.9 | 1,043.6 | 1,049.3 | 1,117.5 | 1,773.6 | 1,577.3 | — | — | 560.9 | 488.8 | 522.8 | 450.1 | 312.7 | 281.9 | 273.4 |
| Cost of Revenues | 339.9 | 326.2 | — | 705.4 | 693.1 | 748.1 | 537.0 | 433.5 | 322.3 | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | 317.6 | 383.0 | 891.3 | 925.2 | — | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 181.2 | 186.1 | 308.0 | 368.4 | 339.5 | 348.7 | 304.1 | 273.5 | 202.5 | 142.9 | 143.1 | 121.1 | 108.6 | 87.9 | 76.0 | 74.3 |
| R&D Expenses | 45.3 | 53.2 | 70.7 | 111.4 | 188.3 | 235.2 | 237.9 | 226.2 | 142.8 | 97.4 | 106.9 | 119.2 | 104.7 | 119.9 | 120.2 | 124.8 |
| Operating Income | (66.0) | 100.1 | (108.7) | (726.4) | (170.0) | 341.4 | 438.5 | 114.1 | 89.8 | 124.3 | 105.5 | 141.5 | 89.2 | 42.8 | 30.0 | 32.1 |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 59.3 | — | 87.9 | 37.3 | 34.5 | 31.3 | 38.4 | 9.9 | 6.6 | 7.6 | 6.5 | 8.2 | 0.0 | 0.0 | 0.0 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | 1.8 | 1.1 | 0.6 | 0.3 | 0.1 | 0.1 | 0.1 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | 4.8 | 6.5 | 6.0 | 7.9 | (0.1) | (0.1) | (0.1) |
| Other Non-Operating Income / Expenses | (80.0) | (17.3) | (34.2) | (4.8) | (49.0) | (38.2) | (26.6) | (36.7) | (8.3) | (5.7) | (6.3) | (5.8) | (5.0) | 0.6 | 2.1 | (0.2) |
| Asset Writedown | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 | 1.2 | — | — |
| EBT, Incl. Unusual Items | (146.0) | 82.8 | (142.9) | (731.2) | (219.0) | 303.2 | 407.2 | 77.4 | 81.5 | 118.6 | 99.2 | 135.7 | 84.2 | 43.4 | 32.1 | 31.9 |
| Income Tax Expense | 30.8 | 30.2 | 47.7 | 29.3 | (7.4) | 83.7 | 106.1 | 22.9 | 18.8 | 36.0 | 36.7 | 44.3 | 29.9 | 13.1 | 13.9 | 15.8 |
| Earnings from Continuing Operations | — | — | — | — | — | — | — | — | 62.7 | 82.6 | 62.5 | — | — | — | — | — |
| Net Income | ||||||||||||||||
| Minority Interest | — | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | (0.9) | (5.4) | (6.9) |
| Net Income | (176.8) | 52.6 | (190.6) | (760.5) | (211.6) | 219.5 | 305.8 | 54.5 | 62.7 | 82.6 | 51.8 | 62.9 | 36.7 | 31.1 | 23.5 | 23.0 |
| Per Share | ||||||||||||||||
| Basic EPS | (3.43) | 0.98 | (3.60) | (14.85) | (4.22) | 4.10 | 5.80 | 1.06 | 1.25 | 1.98 | 1.29 | 1.63 | 0.98 | 0.86 | 0.65 | 0.65 |
| Diluted EPS | (3.43) | 0.93 | (3.60) | (14.85) | (4.22) | 4.06 | 5.68 | 1.04 | 1.22 | 1.71 | 1.13 | 1.41 | 0.88 | 0.85 | 0.65 | 0.64 |
| Basic Weighted Avg Shares | 51.6 | 53.5 | 53.0 | 51.2 | 50.1 | 53.5 | 52.7 | 51.5 | 50.1 | 41.8 | 40.2 | 38.6 | 37.3 | 36.2 | 36.1 | 35.7 |
| Diluted Weighted Avg Shares | 51.6 | 56.7 | 53.0 | 51.2 | 50.1 | 54.1 | 53.8 | 52.4 | 51.4 | 50.3 | 49.3 | 47.3 | 45.8 | 36.7 | 36.4 | 36.2 |
| Supplemental | ||||||||||||||||
| EBITDA | — | 195.9 | 0.1 | (601.3) | (26.7) | 465.2 | 488.6 | 163.6 | 126.1 | 156.5 | 133.5 | 165.3 | 111.5 | 59.8 | 41.2 | 41.5 |
| EBIT | (66.0) | 100.1 | (108.7) | (726.4) | (170.0) | 341.4 | 438.5 | 114.1 | 89.8 | 124.3 | 105.5 | 141.5 | 89.2 | 42.8 | 30.0 | 32.1 |
| Effective Tax Rate | -21.1% | — | — | -4.0% | 3.4% | 27.6% | 26.1% | 29.6% | 23.1% | 30.4% | 37.0% | 32.6% | 35.5% | 30.2% | 43.4% | 49.6% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.